

Stromal Cell Derived Factor 1 - Pipeline Review, H2 2019

<https://marketpublishers.com/r/S5BAF28A0334EN.html>

Date: December 2019

Pages: 66

Price: US\$ 3,500.00 (Single User License)

ID: S5BAF28A0334EN

Abstracts

Stromal Cell Derived Factor 1 - Pipeline Review, H2 2019

SUMMARY

Stromal Cell Derived Factor 1 (C-X-C Motif Chemokine 12 or Intercrine Reduced In Hepatomas or SDF1 or Pre B Cell Growth Stimulating Factor or CXCL12) pipeline Target constitutes close to 8 molecules. Out of which approximately 6 molecules are developed by companies and remaining by the universities/institutes. The latest report Stromal Cell Derived Factor 1 - Pipeline Review, H2 2019, outlays comprehensive information on the Stromal Cell Derived Factor 1 (C-X-C Motif Chemokine 12 or Intercrine Reduced In Hepatomas or SDF1 or Pre B Cell Growth Stimulating Factor or CXCL12) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Stromal Cell Derived Factor 1 (C-X-C Motif Chemokine 12 or Intercrine Reduced In Hepatomas or SDF1 or Pre B Cell Growth Stimulating Factor or CXCL12) - Stromal cell-derived factor 1 (SDF1) or C-X-C motif chemokine 12 (CXCL12) is a chemokine protein encoded by the CXCL12 gene. It activates the C-X-C chemokine receptor CXCR4 to induce a rapid and transient rise in the level of intracellular calcium ions and chemotaxis. It binds to atypical chemokine receptor ACKR3, which activates the beta-arrestin pathway and acts as a scavenger receptor for SDF-1. It acts as a positive regulator of monocyte migration and a negative regulator of monocyte adhesion via the LYN kinase. It stimulates migration of monocytes and T-lymphocytes through its receptors, CXCR4 and ACKR3, and decreases monocyte adherence to surfaces coated with ICAM-1.

The molecules developed by companies in Phase II and Preclinical stages are 4 and 2 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 1 and 1 molecules, respectively. Report covers products from therapy areas Oncology, Cardiovascular, Central Nervous System, Gastrointestinal, Genetic Disorders and Immunology which include indications Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Pancreatic Ductal Adenocarcinoma, B-Cell Chronic Lymphocytic Leukemia, Chronic Heart Failure, Critical Limb Ischemia, Fecal Incontinence, Glioblastoma Multiforme (GBM), Lung Cancer, Metastatic Cancer, Metastatic Colorectal Cancer, Myelodysplastic Syndrome, Ovarian Cancer, Pancreatic Cancer, Pancreatic Islet Transplant Rejection, Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD), Prostate Cancer, Refractory Acute Myeloid Leukemia, Relapsed Multiple Myeloma, Traumatic Brain Injury, WHIM Syndrome (Warts, Hypogammaglobulinemia and Infections and Myelokathexis).

Furthermore, this report also reviews key players involved in Stromal Cell Derived Factor 1 (C-X-C Motif Chemokine 12 or Intercrine Reduced In Hepatomas or SDF1 or Pre B Cell Growth Stimulating Factor or CXCL12) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

SCOPE

The report provides a snapshot of the global therapeutic landscape for Stromal Cell Derived Factor 1 (C-X-C Motif Chemokine 12 or Intercrine Reduced In Hepatomas or SDF1 or Pre B Cell Growth Stimulating Factor or CXCL12)

The report reviews Stromal Cell Derived Factor 1 (C-X-C Motif Chemokine 12 or Intercrine Reduced In Hepatomas or SDF1 or Pre B Cell Growth Stimulating Factor or CXCL12) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which

includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Stromal Cell Derived Factor 1 (C-X-C Motif Chemokine 12 or Intercrine Reduced In Hepatomas or SDF1 or Pre B Cell Growth Stimulating Factor or CXCL12) targeted therapeutics and enlists all their major and minor projects

The report assesses Stromal Cell Derived Factor 1 (C-X-C Motif Chemokine 12 or Intercrine Reduced In Hepatomas or SDF1 or Pre B Cell Growth Stimulating Factor or CXCL12) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Stromal Cell Derived Factor 1 (C-X-C Motif Chemokine 12 or Intercrine Reduced In Hepatomas or SDF1 or Pre B Cell Growth Stimulating Factor or CXCL12) targeted therapeutics

REASONS TO BUY

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Stromal Cell Derived Factor 1 (C-X-C Motif Chemokine 12 or Intercrine Reduced In Hepatomas or SDF1 or Pre B Cell Growth Stimulating Factor or CXCL12)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Stromal Cell Derived Factor 1 (C-X-C Motif Chemokine 12 or Intercrine Reduced In Hepatomas or SDF1 or Pre B Cell Growth Stimulating Factor or CXCL12) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Contents

Introduction

Global Markets Direct Report Coverage

Stromal Cell Derived Factor 1 (C-X-C Motif Chemokine 12 or Intercrine Reduced In Hepatomas or SDF1 or Pre B Cell Growth Stimulating Factor or CXCL12) - Overview
Stromal Cell Derived Factor 1 (C-X-C Motif Chemokine 12 or Intercrine Reduced In Hepatomas or SDF1 or Pre B Cell Growth Stimulating Factor or CXCL12) -

Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Stromal Cell Derived Factor 1 (C-X-C Motif Chemokine 12 or Intercrine Reduced In Hepatomas or SDF1 or Pre B Cell Growth Stimulating Factor or CXCL12) -

Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Stromal Cell Derived Factor 1 (C-X-C Motif Chemokine 12 or Intercrine Reduced In Hepatomas or SDF1 or Pre B Cell Growth Stimulating Factor or CXCL12) - Companies Involved in Therapeutics Development

Biokine Therapeutics Ltd

Chimerix Inc

Juventas Therapeutics Inc

Noxxon Pharma AG

OncoTrap Inc

TikoMed AB

Stromal Cell Derived Factor 1 (C-X-C Motif Chemokine 12 or Intercrine Reduced In Hepatomas or SDF1 or Pre B Cell Growth Stimulating Factor or CXCL12) - Drug Profiles

BKT-300 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

dociparstat sodium - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

IBsolvMIR - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

JVS-100 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

olaptosed pegol - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

OT-1 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit CXCL12 for WHIM Syndrome - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit CXCL12 for Metastatic Cancer - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Stromal Cell Derived Factor 1 (C-X-C Motif Chemokine 12 or Intercline Reduced In Hepatomas or SDF1 or Pre B Cell Growth Stimulating Factor or CXCL12) - Dormant Products

Stromal Cell Derived Factor 1 (C-X-C Motif Chemokine 12 or Intercline Reduced In Hepatomas or SDF1 or Pre B Cell Growth Stimulating Factor or CXCL12) - Discontinued Products

Stromal Cell Derived Factor 1 (C-X-C Motif Chemokine 12 or Intercline Reduced In Hepatomas or SDF1 or Pre B Cell Growth Stimulating Factor or CXCL12) - Product Development Milestones

Featured News & Press Releases

Dec 10, 2019: Chimerix presents updated results from phase 2 clinical trial of DSTAT in refractory myelodysplastic syndrome and acute myeloid leukemia at American Society of Hematology Annual Meeting

Oct 17, 2019: Noxxon Pharma studies combination therapy for brain cancer

Sep 29, 2019: NOXXON presents latest clinical data from phase 1/2 NOX-A12 / Keytruda combination trial at the ESMO Congress

Sep 18, 2019: NOXXON to present latest clinical data from NOX-A12 / Keytruda combination trial at the ESMO Congress

Sep 12, 2019: NOXXON initiates patient recruitment for phase 1/2 Clinical Trial combining NOX-A12 & Radiotherapy for the treatment of Brain Cancer Patients

Jun 24, 2019: NOXXON announces leading international pharma to evaluate NOX-A12 in new indication

Apr 01, 2019: Noxxon presents updated results from phase 1/2 NOX-A12 /Keytruda combination trial at AACR 2019

Mar 04, 2019: TFS International appointed CRO representative for TIKOMED's phase 2 study in clinical islet transplantation

Feb 28, 2019: NOXXON to present latest clinical data from NOX-A12 / Keytruda combination trial at the 2019 AACR Annual Meeting

Feb 27, 2019: Noxxon Files application for phase 1/2 clinical trial combining NOX-A12 & radiotherapy for the treatment of Brain Cancer Patients

Dec 14, 2018: NOXXON announces key findings that NOX-A12 plus Keytruda induces an immune response and results in clinical benefit for patients

Dec 10, 2018: NOXXON to present latest clinical data from Nox-A12 / Keytruda combination trial at Esmo Immuno-Oncology Congress

Nov 30, 2018: TIKOMED Granted Permission for Phase 2 Clinical Trial in Islet Cell Transplantation by the Swedish Medical Product Agency

Nov 21, 2018: NOXXON to launch NOX-A12 with radiotherapy clinical trial in patients with brain cancer

Nov 19, 2018: TIKOMED granted permission for phase 2 clinical trial in islet cell transplantation by the Swedish Medical Product Agency

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Indication, H2 2019
Number of Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Number of Products under Investigation by Universities/Institutes, H2 2019
Products under Investigation by Universities/Institutes, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Pipeline by Biokine Therapeutics Ltd, H2 2019
Pipeline by Chimerix Inc, H2 2019
Pipeline by Juventas Therapeutics Inc, H2 2019
Pipeline by Noxxon Pharma AG, H2 2019
Pipeline by OncoTrap Inc, H2 2019
Pipeline by TikoMed AB, H2 2019
Dormant Products, H2 2019
Dormant Products, H2 2019 (Contd..1), H2 2019
Dormant Products, H2 2019 (Contd..2), H2 2019
Discontinued Products, H2 2019

List Of Figures

LIST OF FIGURES

Number of Products under Development by Stage of Development, H2 2019

Number of Products under Development by Therapy Areas, H2 2019

Number of Products under Development by Top 10 Indications, H2 2019

Number of Products by Mechanism of Actions, H2 2019

Number of Products by Stage and Mechanism of Actions, H2 2019

Number of Products by Routes of Administration, H2 2019

Number of Products by Stage and Routes of Administration, H2 2019

Number of Products by Molecule Types, H2 2019

Number of Products by Stage and Molecule Types, H2 2019

COMPANIES MENTIONED

Biokine Therapeutics Ltd

Chimerix Inc

Juventas Therapeutics Inc

Noxxon Pharma AG

OncoTrap Inc

TikoMed AB

I would like to order

Product name: Stromal Cell Derived Factor 1 - Pipeline Review, H2 2019

Product link: <https://marketpublishers.com/r/S5BAF28A0334EN.html>

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/S5BAF28A0334EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970